Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention

Andrew J. Dannenberg, Scott M. Lippman, Jason R. Mann, Kotha Subbaramaiah, Raymond N. DuBois

Research output: Contribution to journalReview article

309 Scopus citations

Abstract

Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

Original languageEnglish (US)
Pages (from-to)254-266
Number of pages13
JournalJournal of Clinical Oncology
Volume23
Issue number2
DOIs
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention'. Together they form a unique fingerprint.

  • Cite this

    Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005). Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. Journal of Clinical Oncology, 23(2), 254-266. https://doi.org/10.1200/JCO.2005.09.112